Uveitic
glaucoma

Discover
the unmet need
of patients with uveitic glaucoma

Discover
the unmet need
of patients with
uveitic glaucoma

a rare and blinding
disease of the eye.

a rare and blinding
disease of the eye.

Uveitic glaucoma is a rare, blinding, chronic and still not well-known ocular disease.
Its diagnosis requires special attention, and treatment is a real challenge. It is considered an end-stage disease, comprised of two distinct eye diseases, each of them serious and complex by itself: non infectious uveitis and glaucoma.

Non Infectious Uveitis

is an inflammatory
blinding disease of the eye.

is an inflammatory blinding disease of the eye.

Glaucoma

is a disease that damages the optic nerve, and is one of the leading causes of blindness worldwide.

is a disease that damages the optic nerve, and one of the leading causes of blindness worldwide.

“Secondary glaucoma
is one of the major
causes of permanent
visual loss and blindness
in non-infectious
anterior uveitis.”

“Secondary glaucoma is one of the major causes of permanent visual loss and blindness in non-infectious anterior uveitis.”

Uveitic glaucoma in numbers

30%

Of uveitis patients
develop also glaucoma –
uveitic glaucoma

>35

Is the mean
age of a
uveitic patient

30,000

New cases of blindness per year
in the U.S. due to uveitis and
uveitic glaucoma

>100,000

Patients with
uveitic glaucoma
in the U.S.

20

Years to become blind
in at least one eye
due to glaucoma

$ 27.5B

Estimated economic burden of visual impairment in the U.S. population younger than 40 years old

Early diagnosis and proper intervention are crucial, as many patients
with uveitis are young, and need to preserve eyesight for many decades.

Uveitic glaucoma
in numbers

30%

Of uveitis patients develop also glaucoma – uveitic glaucoma

>100,000

Patients with uveitic glaucoma
in the United States

>35

Is the mean age
of a uveitic patient

20

Years to become blind in at least one eye due to glaucoma

30,000

New cases of blindness per year in the U.S. due to uveitis and uveitic glaucoma

$ 27.5B

Estimated economic burden of visual impairment in the U.S. population younger than 40 years old

Early diagnosis and proper intervention are crucial, as many patients with uveitis are young, and need to preserve eyesight for many decades.

Uveitic glaucoma is a debilitating disease

Uveitic
glaucoma
is a
debilitating
disease

According to a recent survey, Key Opinion Leaders (KOLs) from the International Uveitis Study Group (IUSG), emphasized the unique characteristics of uveitic glaucoma, including its complexity, the lack of available treatments and the worse prognosis compared to uveitis alone.

KOLs stated that in uveitic glaucoma
there is a significantly higher risk for visual field loss in the long term compared to uveitis alone.

According to a recent survey, Key Opinion Leaders (KOLs) from the International Uveitis Study Group (IUSG), emphasized the unique characteristics of uveitic glaucoma, including its complexity, the lack of available treatments and the worse prognosis compared to uveitis alone.

KOLs stated that in uveitic glaucoma
there is a significantly higher risk for visual field loss in the long term compared to uveitis alone.

Responding KOLs believe that uveitic glaucoma patients require more clinical visits, compared to uveitis patients without glaucoma:

“A potent agent
is needed for the control
of the intraocular
inflammation without elevating
intraocular pressure”

60%

More visits for a uveitic glaucoma patient than a uveitis patient without glaucoma.

More visits for a uveitic glaucoma patient than a uveitis patient without glaucoma.

40%

Longer visits for a uveitic glaucoma patient than a uveitis patient without glaucoma.

Longer visits for a uveitic glaucoma patient than a uveitis patient without glaucoma.

80%

Of KOLs believe that glaucoma surgeries
for uveitic glaucoma
patients, are likely to fail.

Of KOLs believe that glaucoma surgeries for uveitic glaucoma patients, are likely to fail.

The burden of care for
uveitic glaucoma patients
is thus substantially higher
than for uveitis patients
without glaucoma.

The burden of care for
uveitic glaucoma patients is thus substantially higher than for uveitis patients without glaucoma.

“A potent agent is needed for the control of the intraocular inflammation without elevating intraocular pressure”

“As a result of uveitis alone being a rare ocular disease, the familiarity with one of its main and most devastating complications, uveitic glaucoma, is low; even among the general Ophthalmology community and stakeholders. Consequently, it is important to shed some light about its unique complexity, worse prognosis, and great challenges in treatment“, Dr. Stephen Foster, Key Opinion Leader in Ocular Immunology.

Available treatments for uveitis alone are not suitable for uveitic glaucoma. This unmet need calls for greater awareness of the problem, and for development of effective treatments.

Blindness causes the greatest fear

New treatment options are needed to prevent blindness

Blindness severly reduces quality-of-life (of patients and their families). Economic effects are also severe: it reduces productivity and puts burdens on healthcare systems.

Blindness severly reduces quality-of-life (of patients and their families). Economic effects are also severe: it reduces productivity and puts burdens on healthcare systems.

what causes
uveitic glaucoma?

Glaucoma may occur as a complication of uveitis:
inflammatory debris may cause blockage of the
trabecular meshwork (the “drainage system”),
resulting in decreased fluid outflow from the eye, which leads to increased intraocular pressure.

Often, uveitic glaucoma develops as an adverse effect of steroid-based treatments for uveitis.
Steroids can make the trabecular meshwork less permeable to aqueous humour, resulting again in decreased fluid outflow from the eye and increased intraocular pressure.

Glaucoma may occur as a complication of uveitis:
inflammatory debris may cause blockage of the trabecular meshwork (the “drainage system”), resulting in decreased fluid outflow from the eye, which leads to increased intraocular pressure.

Often, uveitic glaucoma develops as an adverse effect of steroid-based treatments for uveitis.
Steroids can make the trabecular meshwork less permeable to aqueous humour, resulting again in decreased fluid outflow from the eye and increased intraocular pressure.

Causes Desktop

Is uveitic glaucoma treatable?

There are available treatments for uveitis alone or glaucoma alone

Steroid eye drops are considered very effective in treating uveitis and suppressing the inflammation.

However,

For uveitic glaucoma patients, these pose a “double-edged sword” situation, as steroid eye drops also tend to negatively affect glaucoma by elevating the intraocular pressure.

There are no adequate treatments
for uveitic glaucoma

While available treatments for uveitis alone may be adequate for some patients; for uveitic glaucoma, there are no adequate treatments.

Given the limitations of existing therapies, there is a need for new topical anti-inflammatory agents that are as efficacious as corticosteroids, without the known steroid-associated side effects.

Given the limitations of existing therapies, there is a need for new topical anti-inflammatory agents that are as efficacious as corticosteroids, without the known steroid-associated side effects.

“We definitely
need more
options under our
armamentarium”

“We definitely need more
options under our armamentarium”

“As a result of uveitis alone being a rare ocular disease, the familiarity with one of its main and most devastating complications, uveitic glaucoma, is low; even among the general Ophthalmology community and stakeholders.

Consequently, it is important to shed some light about its unique complexity, worse prognosis, and great challenges in treatment“,

Dr. Stephen Foster, Key Opinion Leader in Ocular Immunology.

“As a result of uveitis alone being a rare ocular disease, the familiarity with one of its main and
most devastating complications, uveitic glaucoma, is low; even among the general
Ophthalmology community and stakeholders. Consequently, it is important to shed some light
about its unique complexity, worse prognosis, and great challenges in treatment“, Dr. Stephen Foster, Key Opinion Leader in Ocular Immunology.

Attendees of ARVO (Association for Research in Vision and Ophthalmology) 2023 Annual meeting are welcome to view via this link the recording of a SIG (Special Interest Group) about Uveitic Glaucoma, that took place on Sep 28, 2023. The recording will be available till 31-Dec-23.

suggested further reading

suggested
further reading

Tarsier Pharma - Privacy Policy

We at Tarsier Pharma Ltd. (“Tarsier Pharma”, “we”, “us” or “our”) respect your privacy. This Privacy Policy (“Policy”) explains the accepted privacy practices for our online services at our website (uveiticlgaucoma.com). It also describes the rights and options available to you with respect to your personal information.

The Website provides content and information about Tarsier Pharma and its research and development of a novel platform for treatment of ocular inflammatory diseases.

You do not have a legal duty to provide the information and providing it is subject to your unconditional consent. Proving the service of online inquiries on our Website will not be available to those choosing not to provide the information requested.

PERSONAL DATA WE COLLECT
We collect two types of information: information you actively provide us when contacting us or statistical information about use of the Website.

We use your Information in order to contact you about Inquiries you made and/or to operate the Website.

We may use your Information outlined above for the following purposes:

  • Operating the Website and providing its features and functionalities;

  • Contact you about inquiries you made;

  • Send you email communications concerning our products, programs, developments and other related information. We will send you email communication subject to your explicit consent;

You may ‘opt-out’ of using your data for promotional communications at any time by following the “unsubscribe” link located at the bottom of each message. By doing so, Tarsier Pharma will only delete the Information which is required to contact you for promotional communications, while the rest of the Information you submitted to us which is necessary in order to provide you with the Website’s services will continue to be processed.

  • Improve and enhance the services and content offered on the Website.

WHEN AND HOW WE SHARE YOUR INFORMATION

We share your Information mainly with our contractors and service providers, strictly for the purpose of helping us with the internal operation of the Website.

We will not share your Information with third parties, except in the events listed below or when you provide your explicit and informed consent:

  • We will share your Information with our service providers (such as our hosting providers) who assist us with the internal operations of our Website and our services.

These companies are authorized to use your Information only as necessary to provide these services to us and not for their own promotional purposes. We do not sell your Information to third parties

  • If you have breached any agreement you have with us (including this Policy), abused your rights to use the Websites, or violated any applicable law, your Information may be shared with the competent authorities, law enforcement and third parties (such as legal counsels and advisors), for the purpose of handling of the violation or breach;

  • If we are required to disclose your Information by a judicial, governmental or regulatory authority;

  • We will share your Information with members of our family group of companies, who help us process the data for the purpose set out above;

  • If the operation of the Websites is organized within a different framework, or through another legal structure or entity (e.g. due to a merger or acquisition), we will share your Information to enable the structural change.

FOR HOW LONG WE KEEP YOUR INFORMATION

We will store your data for as long as we deem necessary for the purposes detailed in this Policy

We retain personal data for as long as necessary to fulfil the purposes we collected it for (as detailed above), including for the purposes of satisfying any legal, accounting, or reporting requirements. We, at Tarsier Pharma, always consider the type of information collected, the amount of information, how sensitive it might be. Accordingly, we determine the appropriate retention period.

We may also anonymize your Information so that it can no longer be associated with you, in which case we will use such Information without further notice to you.

HOW DO WE PROTECT YOUR INFORMATION?

We implement measures to reduce the risks of damage and unauthorized access or use of information, including when data is transferred outside the E.U.

Security Measures. We implement measures to reduce the risks of damage, loss of Information and unauthorized access or use of Information. We also request our affiliates to implement such measures in order to secure the Information we provide them. However, although efforts are made to secure your Information, we cannot guarantee its absolute protection.

Cross-Border Data Transfers. We are based in Israel. Information we collect from you will be processed in Israel, which is recognized by the European Commission as having adequate protection for personal data. Certain information may be stored externally via cloud services. We will only transfer your personal information to a country or company which has been deemed to have an adequate level of data protection by the EU commission, or under other adequate safeguards determined under the applicable law.

ADDITIONAL INFORMATION FOR E.U RESIDENTS

Controller. Tarsier Pharma Ltd. is the data controller for the purposes of the personal data we collect via the Website and for the performance of the services offered through the Website.

LEGAL BASIS FOR PROCESSING YOUR DATA

  • The legal basis for processing and collecting Inquiry Information is its necessity for the provision of feedback, comment or service in response to your inquiry;

  • The legal basis for processing and collecting Analytical Information is our legitimate interests in operating our website, ongoing management of our business and business development;

  • The legal basis for collecting and processing your information for Promotional Communications is your explicit consent;

YOUR RIGHTS. You have the following rights under the GDPR:

  • Right to Access. You have a right to access your personal data that we process and receive a copy of it.

  • Right to Rectification. You have the right to ask us to rectify inaccurate personal data concerning you and to have incomplete personal data completed.

  • Right to Data Portability. You have a right to receive the personal data that you provided to us, in a structured, commonly used and machine-readable format. You have the right to transmit this data to a third party. Where technically feasible, you have the right that your personal data be transmitted directly from us to a third party you designated.

  • Right to Withdraw Consent. You have the right to withdraw your consent for processing your personal data at any time. If you do that, we will not collect any further personal data, but we will further process the data we already collected for reasons described in this Policy. Withdrawing your consent will not affect the lawfulness of data processing we carried out based on your consent before such withdrawal.

  • Right to Object. If you previously agreed that your personal data may be used for other purposes other than registering and/or placing an order, you may have a right to object to the use of your personal data for such additional purposes.

  • Right to Restrict. You have the right to restrict processing of your personal data (except for storing it) if you contest the accuracy of your personal data, for a period enabling us to verify its accuracy; if you believe that the processing is unlawful and you opposes the erasure of the personal data and requests instead to restrict its use; if we no longer need the personal data for the purposes outlined in this Policy, but they are required by you to establish, exercise or defence relating to legal claims, or if you object to processing, pending the verification whether our legitimate grounds for processing override yours.

  • Right to be Forgotten. Under certain circumstances, such as when you withdraw your consent, you have the right to ask us to erase your personal data. However, we may still process your personal data if it is necessary to comply with a legal obligation we are subject to under laws in EU Member States.

If you believe your right have been infringed, you can lodge a complaint with a supervisory authority operating under the GDPR. For a list of supervisory authorities in the EU, click here.

Representation for data subjects in the EU
We value your privacy and your rights as a data subject and have therefore appointed Prighter Group with its local partners as our privacy representative and your point of contact.
Prighter gives you an easy way to exercise your privacy-related rights (e.g. requests to access or erase personal data). If you want to contact us via our representative Prighter or make use of your data subject rights, please visit the following website. https://prighter.com/q/11999524960

POLICY AMENDMENTS

From time to time, we may change this Policy. We will provide you notice of such changes through the Website interface.

CONTACT US

You may contact us  via our email at info@tarsierpharma.com, We will do our best to resolve your issue promptly.

Last update: April, 2022